ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer-Reference-Cited by-同舟云学术

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

Published:2021-12 Issue:12 Volume:32 Page:1475-1495
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Gennari A.,André F.,Barrios C.H.,Cortés J.,de Azambuja E.,DeMichele A.,Dent R.,Fenlon D.,Gligorov J.,Hurvitz S.A.,Im S.-A.,Krug D.,Kunz W.G.,Loi S.,Penault-Llorca F.,Ricke J.,Robson M.,Rugo H.S.,Saura C.,Schmid P.,Singer C.F.,Spanic T.,Tolaney S.M.,Turner N.C.,Curigliano G.,Loibl S.,Paluch-Shimon S.,Harbeck N.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference92 articles.

1. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis;Gao;Lancet Oncol,2020

2. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer;Schmid;N Engl J Med,2018

3. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study;Swain;Lancet Oncol,2020

4. Trastuzumab emtansine for HER2-positive advanced breast cancer;Verma;N Engl J Med,2012

5. Sacituzumab govitecan in metastatic triple-negative breast cancer;Bardia;N Engl J Med,2021

Cited by 646 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolving therapeutics and ensuing cardiotoxicities in triple-negative breast cancer;Cancer Treatment Reviews;2024-11

2. The impact of previous therapy on overall-survival in registration clinical trials for 1st line metastatic breast cancer a systemic review;Critical Reviews in Oncology/Hematology;2024-10

3. Risk of radionecrosis in HER2-positive breast cancer with brain metastasis receiving trastuzumab emtansine (T-DM1) and brain stereotactic radiosurgery;Radiotherapy and Oncology;2024-10

4. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer;New England Journal of Medicine;2024-09-14

5. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial;Nature Medicine;2024-09-13